Literature DB >> 17879924

Infection control in jails and prisons.

Joseph A Bick1.   

Abstract

At the end of 2005, approximately 7 million people (or 1 of every 33 American adults) were either in jail, in prison, or on parole. Compared with the general public, newly incarcerated inmates have an increased prevalence of human immunodeficiency virus infection, hepatitis B virus infection, hepatitis C virus infection, syphilis, gonorrhea, chlamydia, and Mycobacterium tuberculosis infection. While incarcerated, inmates are at an increased risk for the acquisition of blood-borne pathogens, sexually transmitted diseases, methicillin-resistant Staphylococcus aureus infection, and infection with airborne organisms, such as M. tuberculosis, influenza virus, and varicella-zoster virus. While incarcerated, inmates interact with hundreds of thousands of correctional employees and millions of annual visitors. Most inmates are eventually released to interact with the general public. Tremendous opportunities exist for infectious diseases specialists and infection-control practitioners to have an impact on the health of correctional employees, the incarcerated, and the communities to which inmates return. This article presents a brief review of some of the most important infection-control challenges and opportunities within the correctional setting.

Entities:  

Mesh:

Year:  2007        PMID: 17879924     DOI: 10.1086/521910

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  60 in total

1.  Filling the gap: the importance of Medicaid continuity for former inmates.

Authors:  Sarah E Wakeman; Margaret E McKinney; Josiah D Rich
Journal:  J Gen Intern Med       Date:  2009-04-18       Impact factor: 5.128

2.  Fulfilling the mission of academic medicine: training residents in the health needs of prisoners.

Authors:  Sarah E Wakeman; Josiah D Rich
Journal:  J Gen Intern Med       Date:  2010-05       Impact factor: 5.128

3.  Epidemiological and biological determinants of Staphylococcus aureus clinical infection in New York State maximum security prisons.

Authors:  Benjamin A Miko; Montina Befus; Carolyn T A Herzig; Dhritiman V Mukherjee; Zoltan L Apa; Ruo Yu Bai; Joshua P Tanner; Dana Gage; Maryann Genovese; Carl J Koenigsmann; Elaine L Larson; Franklin D Lowy
Journal:  Clin Infect Dis       Date:  2015-03-25       Impact factor: 9.079

4.  Incarceration and Health.

Authors:  Michael Massoglia; William Alex Pridemore
Journal:  Annu Rev Sociol       Date:  2015-08

5.  Epidemiology of methicillin-resistant Staphylococcus aureus among incarcerated population in Hawai'i, 2000-2005.

Authors:  Fenfang Li; F DeWolfe Miller; Paul V Effler
Journal:  Hawaii Med J       Date:  2010-04

6.  Competing imperatives? Moral and public health duties of preventing and treating infectious disease in prisons.

Authors:  José de Arimatéia da Cruz; Leigh E Rich
Journal:  J Bioeth Inq       Date:  2014-01-24       Impact factor: 1.352

7.  The rise of methicillin-resistant staphylococcus aureus in U.S. correctional populations.

Authors:  Bianca Malcolm
Journal:  J Correct Health Care       Date:  2011-05-13

8.  Serological Susceptibility to Varicella Among U.S. Immigration and Customs Enforcement Detainees.

Authors:  Aiden K Varan; Edith R Lederman; Shanon S Stous; Diana Elson; Jennifer L Freiman; Mona Marin; Adriana S Lopez; William M Stauffer; Rachael H Joseph; Stephen H Waterman
Journal:  J Correct Health Care       Date:  2017-09-25

9.  Opt-out Testing Pilot for Sexually Transmitted Infections Among Immigrant Detainees at 2 Immigration and Customs Enforcement Health Service Corps-Staffed Detention Facilities, 2018.

Authors:  Edith Lederman; Andria Blackwell; Gina Tomkus; Misty Rios; Brent Stephen; Ada Rivera; Philip Farabaugh
Journal:  Public Health Rep       Date:  2020 Jul/Aug       Impact factor: 2.792

Review 10.  Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implications.

Authors:  Shaili Gupta; Frederick L Altice
Journal:  J Urban Health       Date:  2009-01-28       Impact factor: 3.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.